View ValuationAmoéba 将来の成長Future 基準チェック /56Amoébaは、62.7%と47.3%でそれぞれ年率62.7%で利益と収益が成長すると予測される一方、EPSはgrowで64.4%年率。主要情報62.7%収益成長率64.37%EPS成長率Chemicals 収益成長43.6%収益成長率47.3%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日07 May 2026今後の成長に関する最新情報Breakeven Date Change • May 20Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 63% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesBreakeven Date Change • May 20Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. Independent Director Quentin Hua was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 16Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic CropsAmoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation.お知らせ • Mar 26Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,333,333 Price\Range: €0.75 Transaction Features: Subsequent Direct ListingBoard Change • Dec 30Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. Independent Director Quentin Hua was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • May 22Amoéba S.A., Annual General Meeting, Jun 26, 2025Amoéba S.A., Annual General Meeting, Jun 26, 2025. Location: 38 avenue des freres montgolfier, chassieu FranceNew Risk • Jun 06New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€3.9m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Negative equity (-€3.9m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.8m net loss in 2 years). Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Market cap is less than US$100m (€24.3m market cap, or US$26.4m).お知らせ • May 25Amoéba S.A., Annual General Meeting, Jun 27, 2024Amoéba S.A., Annual General Meeting, Jun 27, 2024. Location: 38 avenue des freres montgolfier, chassieu FranceNew Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Market cap is less than US$100m (€21.1m market cap, or US$22.1m).New Risk • Sep 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (€27.0m market cap, or US$28.7m).New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (€28.4m market cap, or US$30.7m).New Risk • Jul 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€27.2m market cap, or US$30.5m).Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jul 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Is New 90 Day High Low • Feb 20New 90-day low: €2.50The company is down 9.0% from its price of €2.74 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period.Is New 90 Day High Low • Nov 24New 90-day high: €3.53The company is up 32% from its price of €2.68 on 25 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period.お知らせ • Nov 07Amoéba S.A., Annual General Meeting, May 27, 2021Amoéba S.A., Annual General Meeting, May 27, 2021.Is New 90 Day High Low • Oct 01New 90-day low: €1.52The company is down 47% from its price of €2.90 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.業績と収益の成長予測DB:A1H - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282875N/A112/31/202716113212/31/20265-5-6-2312/31/20251-8-7-6N/A9/30/20251-8N/AN/AN/A6/30/20251-7-5-4N/A3/31/20251-7-5-4N/A12/31/20241-7-5-4N/A9/30/20241-10N/AN/AN/A6/30/20241-13-12-7N/A3/31/20241-14-12-7N/A12/31/20231-14-13-7N/A9/30/20230-11-9-5N/A6/30/2023N/A-7-6-4N/A3/31/2023N/A-8-5-4N/A12/31/2022N/A-8-5-4N/A9/30/2022N/A-8-5-4N/A6/30/2022N/A-8-5-5N/A3/31/2022N/A-8-5-4N/A12/31/2021N/A-8-4-4N/A9/30/2021N/A-8-4-4N/A6/30/2021N/A-8-4-4N/A3/31/2021N/A-8-4-4N/A12/31/2020N/A-8-3-3N/A9/30/20200-7-3-3N/A6/30/20200-7-3-3N/A3/31/20200-7-3-3N/A12/31/20190-7-4-3N/A9/30/20190-7N/A-4N/A6/30/20190-7N/A-4N/A3/31/20190-7N/A-5N/A12/31/20180-7N/A-5N/A9/30/20180-7N/A-6N/A6/30/20180-7N/A-6N/A3/31/20180-7N/A-5N/A12/31/20170-6N/A-5N/A9/30/20170-6N/A-5N/A6/30/20170-6N/A-5N/A3/31/20170-6N/A-5N/A12/31/20160-6N/A-6N/A9/30/20160-6N/A-6N/A6/30/20160-5N/A-6N/A3/31/20160-5N/A-5N/A12/31/20150-4N/A-4N/A9/30/20150-3N/A-3N/A6/30/20150-2N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A1Hは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 1.9% ) よりも高い成長率であると考えられます。収益対市場: A1H今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: A1H今後 3 年以内に収益を上げることが予想されます。収益対市場: A1Hの収益 ( 47.3% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: A1Hの収益 ( 47.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A1Hの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 02:24終値2026/05/29 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Amoéba S.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Andrew KeenEdison Investment ResearchGuy SipsKBC Securities NVThomas VrankenKBC Securities NV3 その他のアナリストを表示
Breakeven Date Change • May 20Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Breakeven Date Change • May 20Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. Independent Director Quentin Hua was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 16Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic CropsAmoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation.
お知らせ • Mar 26Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,333,333 Price\Range: €0.75 Transaction Features: Subsequent Direct Listing
Board Change • Dec 30Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. Independent Director Quentin Hua was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • May 22Amoéba S.A., Annual General Meeting, Jun 26, 2025Amoéba S.A., Annual General Meeting, Jun 26, 2025. Location: 38 avenue des freres montgolfier, chassieu France
New Risk • Jun 06New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€3.9m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Negative equity (-€3.9m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.8m net loss in 2 years). Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Market cap is less than US$100m (€24.3m market cap, or US$26.4m).
お知らせ • May 25Amoéba S.A., Annual General Meeting, Jun 27, 2024Amoéba S.A., Annual General Meeting, Jun 27, 2024. Location: 38 avenue des freres montgolfier, chassieu France
New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.6% average weekly change). Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Market cap is less than US$100m (€21.1m market cap, or US$22.1m).
New Risk • Sep 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (€27.0m market cap, or US$28.7m).
New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (€28.4m market cap, or US$30.7m).
New Risk • Jul 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€27.2m market cap, or US$30.5m).
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jul 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Is New 90 Day High Low • Feb 20New 90-day low: €2.50The company is down 9.0% from its price of €2.74 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: €3.53The company is up 32% from its price of €2.68 on 25 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period.
お知らせ • Nov 07Amoéba S.A., Annual General Meeting, May 27, 2021Amoéba S.A., Annual General Meeting, May 27, 2021.
Is New 90 Day High Low • Oct 01New 90-day low: €1.52The company is down 47% from its price of €2.90 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.